Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Venkatraman N, Tiono AB, Bowyer G, Bellamy DG, Stockdale LK, Powlson J, Collins KA, Coulibaly S, Datoo MS, Silman D, Ouedraogo A, Nébié I, Imoukhuede EB, Brod F, Folegatti P, Dickinson-Craig E, Jamieson S, Bougouma EC, Wright D, Diarra A, Bliss CM, Morter R, Glenn G, Fries LF, Reimer JM, Lövgren-Bengtsson K, Baker M, Poulton I, Moyle S, Berrie E, Green N, Mukhopadhyay E, Viebig NK, Angus B, Lawrie A, Roberts R, Gilbert SC, Lewis DJM, Sirima SB, Ewer KJ, Hill AVS. Venkatraman N, et al. Among authors: folegatti p. Lancet Microbe. 2024 Dec 17:100868. doi: 10.1016/S2666-5247(24)00084-3. Online ahead of print. Lancet Microbe. 2024. PMID: 39805302 Free article.
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Venkatraman N, Silman D, Bellamy D, Stockdale L, Bowyer G, Edwards NJ, Griffiths O, Lopez FR, Powlson J, Mair C, Folegatti PM, Datoo MS, Morter R, Minassian AM, Poulton I, Collins KA, Brod F, Angell-Manning P, Berrie E, Brendish N, Glenn G, Fries L, Baum J, Blagborough AM, Roberts R, Lawrie AM, Angus B, Lewis DJM, Faust SN, Ewer KJ, Hill AVS. Venkatraman N, et al. Among authors: folegatti pm. Lancet Microbe. 2025 Jan 9:100867. doi: 10.1016/S2666-5247(24)00083-1. Online ahead of print. Lancet Microbe. 2025. PMID: 39805301 Free article.
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
Satti I, Marshall JL, Harris SA, Wittenberg R, Tanner R, Lopez Ramon R, Wilkie M, Ramos Lopez F, Riste M, Wright D, Peralta Alvarez MP, Williams N, Morrison H, Stylianou E, Folegatti P, Jenkin D, Vermaak S, Rask L, Cabrera Puig I, Powell Doherty R, Lawrie A, Moss P, Hinks T, Bettinson H, McShane H. Satti I, et al. Among authors: folegatti p. Lancet Infect Dis. 2024 Aug;24(8):909-921. doi: 10.1016/S1473-3099(24)00143-9. Epub 2024 Apr 12. Lancet Infect Dis. 2024. PMID: 38621405 Free article. Clinical Trial.
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Jenkin D, Wright D, Folegatti PM, Platt A, Poulton I, Lawrie A, Tran N, Boyd A, Turner C, Gitonga JN, Karanja HK, Mugo D, Ewer KJ, Bowden TA, Gilbert SC, Charleston B, Kaleebu P, Hill AVS, Warimwe GM. Jenkin D, et al. Among authors: folegatti pm. Lancet Infect Dis. 2023 Aug;23(8):956-964. doi: 10.1016/S1473-3099(23)00068-3. Epub 2023 Apr 13. Lancet Infect Dis. 2023. PMID: 37060917 Free PMC article. Clinical Trial.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Voysey M, Flaxman A, Aboagye J, Aley PK, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Charlton S, Clutterbuck EA, Davies S, Dold C, Edwards NJ, Ewer KJ, Faust SN, Folegatti PM, Fowler J, Gilbride C, Gilbert SC, Godfrey L, Hallis B, Humphries HE, Jenkin D, Kerridge S, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Snape MD, Song R, Thomas KM, Ulaszewska M, Woods D, Wright D, Pollard AJ, Lambe T. Voysey M, et al. Among authors: folegatti pm. Clin Exp Immunol. 2023 Mar 24;211(3):280-287. doi: 10.1093/cei/uxad013. Clin Exp Immunol. 2023. PMID: 36729167 Free PMC article.
Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics.
Salkeld J, Themistocleous Y, Barrett JR, Mitton CH, Rawlinson TA, Payne RO, Hou MM, Khozoee B, Edwards NJ, Nielsen CM, Sandoval DM, Bach FA, Nahrendorf W, Ramon RL, Baker M, Ramos-Lopez F, Folegatti PM, Quinkert D, Ellis KJ, Poulton ID, Lawrie AM, Cho JS, Nugent FL, Spence PJ, Silk SE, Draper SJ, Minassian AM. Salkeld J, et al. Among authors: folegatti pm. Front Immunol. 2022 Aug 22;13:984323. doi: 10.3389/fimmu.2022.984323. eCollection 2022. Front Immunol. 2022. PMID: 36072606 Free PMC article. Clinical Trial.
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Marchevsky NG, Li G, Aley P, Costa Clemens SA, Barrett JR, Belij-Rammerstorfer S, Bibi S, Clutterbuck E, Dold C, Felle S, Flaxman A, Folegatti P, Jenkin D, Gilbert S, Kelly S, Lambe T, Plested E, Ramasamy M, Singh N, Smith H, Taylor S, Weckx L, Pollard AJ, Voysey M; Oxford COVID Vaccine Trial Group. Marchevsky NG, et al. Among authors: folegatti p. EBioMedicine. 2022 Jul;81:104128. doi: 10.1016/j.ebiom.2022.104128. Epub 2022 Jun 30. EBioMedicine. 2022. PMID: 35779491 Free PMC article.
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Folegatti PM, Jenkin D, Morris S, Gilbert S, Kim D, Robertson JS, Smith ER, Martin E, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG). Folegatti PM, et al. Vaccine. 2022 Aug 19;40(35):5248-5262. doi: 10.1016/j.vaccine.2022.06.008. Epub 2022 Jun 14. Vaccine. 2022. PMID: 35715352 Free PMC article.
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
Ratcliff J, Al-Beidh F, Bibi S, Bonsall D, Costa Clemens SA, Estcourt L, Evans A, Fish M, Folegatti PM, Gordon AC, Jay C, Jennings A, Laing E, Lambe T, MacIntyre-Cockett G, Menon D, Mouncey PR, Nguyen D, Pollard AJ, Ramasamy MN, Roberts DJ, Rowan KM, Rynne J, Shankar-Hari M, Williams S, Harvala H, Golubchik T, Simmonds P; AMPHEUS Project, REMAP-CAP Immunoglobulin Domain UK Investigators, and Oxford COVID-19 Vaccine Trial Group. Ratcliff J, et al. Among authors: folegatti pm. J Clin Microbiol. 2022 Apr 20;60(4):e0228321. doi: 10.1128/jcm.02283-21. Epub 2022 Mar 24. J Clin Microbiol. 2022. PMID: 35321556 Free PMC article.
39 results